RxDoctor Payments Data

Robert Jordan

Family · Ahoskie, NCNPI 1336725050

Payments from drug & device makers

$653in general payments, 2019–2025

Across 34 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$145
  • Novo Nordisk$95
  • Amgen$90
  • Lilly USA, LLC$57
  • Novartis$55
  • AbbVie$48
  • plus $162 from 6 others

What the payments were for

  • Food & beverage$653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$653 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,005
Medicare patients
56
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$129,682
FarxigaDapagliflozin Propanediol73$70,429
RybelsusSemaglutide26$59,732
OzempicSemaglutide32$50,539
EliquisApixaban51$42,604
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$40,438
JanuviaSitagliptin Phosphate20$24,656
XareltoRivaroxaban19$18,172
MounjaroTirzepatide14$17,317
Repatha SureclickEvolocumab17$11,029
LinzessLinaclotide12$9,871
Breo ElliptaFluticasone/Vilanterol17$8,203
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$6,239
SymbicortBudesonide/Formoterol Fumarate13$2,924
Atorvastatin Calcium265$2,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$44$129,682103 claims
Novo NordiskRybelsus, Ozempic$95$110,27158 claims
GSKTrelegy Ellipta, Breo Ellipta$145$48,64280 claims
PfizerEliquis$15$42,60451 claims
Lilly USA, LLCMounjaro$57$17,31714 claims
AbbVieLinzess$48$9,87112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Ahoskie

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →